DRAFT — Andres review
Doctor Zuleta · Kylo-11 Content Package · Videos live · Blog live

01 Paper card

Citation card for Sarraju et al. Lancet Kylo-11
Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
Journal
The Lancet — online Aug 28, 2026 (ESC late-breaker, Munich)
Authors
Ashish Sarraju, M.D. (lead, Cleveland Clinic) et al.; Du X, Zhou L, et al.
Study type
Phase 1 first-in-human, double-blind RCT · biomarker + safety (not CV outcomes)
Sponsor
Kylonova Biopharma (Hygieia Pharma / SBP Group) · Phase 2 underway
One-sentence hook: One subcutaneous shot of a gene-silencing RNA cut Lp(a) by roughly half to nearly all — and the highest doses held that drop for almost a year.

02 Videos · HeyGen play boxes

Avatar ecf378a3… · voice az2 f034b93d…. v7 · playable Be proactive outro (no stay vital) — 5-min + 3-min embedded; locked posters.

5-min · Epic explainer

ID bd3085ff322548a48b2930b6d24d2d47 · 6:08
Poster · thumb-5min.png · ChatGPT B 97% DROP Status: v7 · playable · 6:08

3-min · YouTube cut

ID c3a3e066f1f544be97eff961595e1b00 · 3:17
Poster · thumb-3min.png · ChatGPT C ASK FOR THIS LAB Status: v6 · playable · 3:30

Reels / Shorts · Test Lp(a)

ID bf9a460468384102b81c7a14cf2f6d20 · 0:45
Poster · thumb-reels.png · 9:16 reframed · ChatGPT E TEST Lp(a) Status: v9 · playable · 0:45

03 Companion blog

Full article inlined below. Also available as a standalone page.

Read the companion blog · The lab most people never get
Dr. Andres Zuleta, MD

Companion blog · Kylo-11 / Lp(a)

The lab most people never get

A Lancet Phase 1 gene-silencing shot lowered lipoprotein(a) for nearly a year. Here is what that means — and what it does not prove yet.

Sep 5, 2026 · Doctor Zuleta / ThriveMed · ~8 min read

There is a cholesterol-related number that can sit quietly in your blood for decades. You usually cannot feel it. Diet and exercise barely move it. And most people who have a high level have never been told the number exists.

That number is lipoprotein(a) — written Lp(a), pronounced “L-P-little-a.” On August 28, 2026, a first-in-human Phase 1 trial of an investigational drug called Kylo-11 was published in The Lancet and presented as a late-breaker at ESC in Munich. One subcutaneous injection reduced Lp(a) by roughly half to nearly all — and at the highest doses, that drop held for about 48 weeks.

This is exciting Phase 1 science. It is not proof that Kylo-11 prevents heart attacks. Let me walk you through it the way I would with a patient in clinic.

What Lp(a) is — in plain language

Think of Lp(a) as LDL’s genetically stickier cousin. Like LDL (“bad cholesterol”), it is a particle that carries cholesterol in the blood. Because of its structure, elevated Lp(a) can contribute to plaque buildup in artery walls and tip clotting tendency — which is why cardiologists care about it as a heart-disease and stroke risk marker.

The key difference: about 80–90% of your Lp(a) level is inherited. Unlike LDL, lifestyle changes do not meaningfully lower Lp(a). Statins and diet can be powerful for other risk factors — and they still matter for overall heart health — but they are not a reliable dial for this one.

There is still no approved drug specifically designed to lower Lp(a). And Lp(a) remains under-tested. Many people with high levels simply do not know it.

Cleveland Clinic medical illustration of lipoprotein(a)
Cleveland Clinic medical illustration of lipoprotein(a); media use from CCF newsroom Kylo-11 release.

What the study found

Kylo-11 is a long-acting small interfering RNA (siRNA). In simple terms, it is like a mute button for the liver’s Lp(a) factory. The drug delivers a gene-silencing signal to liver cells, reducing production of apo(a) — a building block of Lp(a). With less apo(a) made, the body assembles far fewer Lp(a) particles.

Citation title card for the Lancet Kylo-11 paper
Title card for Sarraju et al., The Lancet (online Aug 28, 2026). Educational citation graphic — not a journal PDF screenshot. DOI: 10.1016/S0140-6736(26)01484-4

Design, in one breath:

  • Phase 1 first-in-human, randomised, double-blind, placebo-controlled trial
  • ~71 people enrolled in China; 70 received a dose (Kylo-11 or placebo)
  • Single subcutaneous injection; follow-up on the order of ~48 weeks / ~11 months
  • Lead author Ashish Sarraju, M.D. (Cleveland Clinic) and colleagues

Results across dosing groups: a single injection reduced Lp(a) by approximately 53–97% at 48 weeks. Participants on the highest doses saw reductions of about 95–97%, with the effect sustained for nearly a year. Public coverage notes durable effect at doses ≥225 mg, with the 600 mg group showing a median reduction around 97%.

Median percent change in Lp(a) over time by dose group
Primary study graph — median % Lp(a) change over time by dose (educational use from published Phase 1 materials / ConsultQD coverage of Sarraju et al., Lancet 2026).
Kylo-11 dose-response bar chart rebuilt from Phase 1 table
Dose–response at ~48 weeks rebuilt from the published Phase 1 table (ConsultQD / Lancet 2026): Placebo +6.6%; 9 mg −53.2%; 30 mg −77.6%; 75 mg −89.3%; 225 mg −94.6%; 450 mg −96.3%; 600 mg −97.0%; 225 mg high-exposure −95.6%. Educational rebuild — not a scanned Lancet panel.
Lancet Kylo-11 title card
Lancet title treatment for Sarraju et al. (online Aug 28, 2026). Companion assets: lancet-cover.gif, paper citation card.
The Lancet cover mark
Citation card

Lancet cover mark + ThriveMed citation card (not a journal PDF screenshot).

On safety: the drug was generally well tolerated in this Phase 1 experience. Coverage and the published findings summary report no serious drug-related adverse events in the trial as described.

Citation card for Sarraju et al. Lancet Kylo-11
Companion citation card (ThriveMed educational asset). Full text may be paywalled on The Lancet / Elsevier.
What this does NOT prove yet

Phase 1 answers safety and biomarker questions in a relatively small first-in-human study. It does not prove that Kylo-11 prevents heart attacks, strokes, or death. Kylo-11 is not approved and not available for routine clinical use. Cardiovascular outcome trials — and larger Phase 2/3 programs — are what tell us whether deep Lp(a) lowering changes events. A Phase 2 trial is already underway (sponsor: Kylonova Biopharma / Hygieia Pharma / SBP Group, collaborating with Cleveland Clinic investigators).

Excitement is fair. Overclaiming is not. A nearly year-long mute on an “untreatable” genetic risk marker is a meaningful signal. Converting that signal into fewer heart attacks is the next chapter — not this one.

What to ask your clinician

You do not need to wait for an investigational drug to act on the part you control today: knowing your number.

Bring these to your next visit

  1. “Can I get a lipoprotein(a) / Lp(a) blood test?” For most people it is a once-in-a-lifetime lab unless something clinical changes.
  2. “How does my Lp(a) fit with my overall risk?” Family history, LDL, blood pressure, diabetes, smoking, and inflammation still matter.
  3. “If my Lp(a) is high, what do we optimize now?” Aggressive management of other risk factors remains the practical playbook while Lp(a)-specific drugs are still in development.
  4. “Should we revisit this as Phase 2/3 data mature?” Reasonable to stay curious — without treating pipeline news as a prescription.
Practical takeaway

You can’t feel high Lp(a). You can’t diet it away. One blood test — often once in a lifetime — tells you where you stand. Ask for it. Bring the result to your clinician. Follow the science as Phase 2 unfolds — but do not wait for a drug to get tested.

Hi — if we haven’t met, I’m Doctor Zuleta. ThriveMed exists to expand human vitality. I write these research decodes to keep the claims honest and the next step clear. Stay curious. Stay vital.

Prefer a dedicated page? Open blog.html (same content, standalone layout).

04 Viewer takeaway / CTA

Takeaway

You can’t “feel” high Lp(a). You can’t diet it away. One blood test — often once in a lifetime — tells you where you stand.

Ask your clinician for a lipoprotein(a) / Lp(a) blood test — a once-in-a-lifetime lab for most people. Know your number. Bring it to your next visit.

Soft secondary: follow the pipeline (Phase 2 underway) — but don’t wait for a drug to get tested.

05 Hooks & analogies

Short Reels / TikTok / IG hooks

20s · Untreatable?
“There’s a cholesterol number diet can’t fix.” Cut to: one shot → up to ~97% drop for nearly a year. Title flash. CTA: ask for Lp(a). Stay vital.
25s · Mute button
“Your liver has an Lp(a) factory. Kylo-11 is a mute button.” Quick mechanism + 95–97% line + Phase 1 caveat sticker.
30s · Most people don’t know
“Most people with high Lp(a) don’t know it.” Genetic 80–90%. Under-tested. New Lancet Phase 1. Get tested once.
35s · Three numbers
On-screen: 53–97% · 48 weeks · Phase 1. Voice explains each. End: “Exciting ≠ approved. Still: know your Lp(a).”
15s · Sticky cousin
“Lp(a) = LDL’s genetically sticky cousin.” Snap to Kylo-11 result + “ask for the lab.”

Analogies

Extra-sticky cholesterol particleLp(a) is like LDL’s genetically stickier cousin: it can cling to artery walls and tip clotting risk, and your “factory setting” is mostly inherited.
Mute button for the liver’s Lp(a) factoryKylo-11’s siRNA is like hitting mute on the liver’s apo(a) production line so far fewer Lp(a) particles get assembled.
Smoke alarm you never installedHigh Lp(a) is a risk many people never measure; testing once is like finally putting a detector on the wall.
Not a lifestyle dialDiet and exercise are powerful for other heart risks, but for Lp(a) the genetic dial barely budges — that’s why a gene-silencing approach is interesting.

06 Asset prompts

How each piece was made — HeyGen video briefs and social prompts, embedded for offline review.

Asset prompts (how each piece was made)
5-min HeyGen
Create a 5 minute video, make sure is at least 5 minutes. inspirational, epic video with cinematic music, Modern with an intro that’s a Hook about what the video is going to be talking about with B roll. In the first 2 seconds start by describing what the video is going to be about with a hook. B roll must be Nat Geo, imax level quality’s That is a visual representation of the subject, at a glance, zooming in into a molecular level. Make sure th animations are scientifically correct animations or B roll of the subject.

FRAMING (CRITICAL): This is about a NEW WAY OF DOING HEALTHCARE — proactive, genetics-aware, clinician-led prevention and risk detection. NEVER use the word "longevity". Never say longevity, longevity medicine, or anti-aging. Use language like: proactive care, knowing your risks early, expanding human vitality through better clinical practice, a new standard of care.

SUBJECT: Kylo-11 (spell exactly Kylo-11, never KYLLO), Lancet 2026 Phase 1 first-in-human long-duration siRNA lowering lipoprotein(a)/Lp(a). Ashish Sarraju, Cleveland Clinic. One SC injection cut Lp(a) ~53–97% at 48 weeks; highest doses ~95–97% for nearly a year. Lp(a) ~80–90% genetic; diet/exercise barely move it; under-tested. Phase 1 safety + biomarker only — NOT proven CV outcome benefit. Phase 2 underway. CTA: ask once for an Lp(a) blood test.

Then introduce Myself as , Hi! if we have not met yet, I am the AI for Dr. zuleta. While he is working clinically and with teams to improve health, i am here sharing his messages. Mention Dr zuleta is the founder of Thrivemed, a company that works to expand human vitality. He writes every script and him and his team read every comment.

Then the subject — inspiring potential AND weaknesses — analogies + animations, the study, inspirational outro.
Analogies: Lp(a) as genetically sticky cholesterol-like particle; Kylo-11 siRNA as mute button for the liver’s Lp(a) factory (apo(a)).

Speech ~1.2x engaging. Lots of B-roll, camera/zoom changes on digital avatar. Don’t say his name more than once. Particle-design twin zoom whole→molecular. When sharing research zoom into TITLE only with highlight animations and show images of the paper. Explain so anyone understands. End with "stay vital" EXACTLY ONCE at the very end — never earlier.

Cinematic effects throughout. B-roll like high-end scientific documentary. Music: Epic cinematic hybrid orchestral 105-115 BPM — massive drum + brass braam open, driving staccato strings + sub-bass, deep brass swells, soaring strings, propulsive bed, crescendo to triumphant climax. Polished and grand. Vary musical sections so it does not feel looped or repetitive.

No invented clinical claims. No longevity wording.
3-min HeyGen
Create a ~3 minute YouTube video (target 2:45–3:15).

Hook in first 2 seconds with Nat Geo/IMAX B-roll of Lp(a) zooming molecular.
Intro once: Hi! if we have not met yet, I am the AI for Dr. zuleta. While he is working clinically and with teams to improve health, i am here sharing his messages. ThriveMed expands human vitality. He writes every script; he and his team read every comment. Name at most once.

FRAMING: NEW WAY OF DOING HEALTHCARE / proactive clinical risk care. NEVER say longevity.

SUBJECT: Kylo-11 (never KYLLO) — Lancet Aug 2026 Phase 1 siRNA for Lp(a). One shot ~53–97% drop at 48 weeks; high doses ~95–97% ~1 year. Sarraju/Cleveland Clinic. Genetic risk; ask for the lab once. Potential + weaknesses: exciting durable lowering; Phase 1 only — not outcome data; Phase 2 underway.

Speech ~1.2x. Lots of B-roll, avatar zooms, particle twin. Paper TITLE zoom only + paper imagery. Analogies + correct molecular animations.

MUSIC (CRITICAL): Epic cinematic hybrid orchestral 105-115 BPM BUT with clear evolving sections — distinct intro hit, mid verse bed, bridge swell, final climax. DO NOT use a short looping/repetitive bed. Music must feel varied and film-scored, not a repeating loop.

OUTRO: Say "stay vital" EXACTLY ONE TIME at the very end. Do not say stay vital earlier. Do not repeat it.

No invented claims. No longevity.
Reels
Create a short vertical Reel for Instagram Reels / TikTok / YouTube Shorts — portrait 9:16, about 45–60 seconds. MAXIMUM cinematic production value: IMAX scientific documentary look, volumetric light, elegant camera moves, molecular zooms that feel premium film — not stock or flat.

Hook in first 2 seconds: most people never get tested for Lp(a); Lancet 2026 one-shot Kylo-11 dropped levels ~95–97% for nearly a year in Phase 1.

Navy scrubs digital twin avatar. Speech ~1.2x. Spell Kylo-11 never KYLLO. NEVER say longevity — frame as proactive healthcare / knowing your inherited risk.

Brief AI-for-Dr-Zuleta only if it fits without killing pace. ThriveMed once max. Name at most once.

Simple explain: Lp(a) inherited; diet won’t fix; siRNA mute button for liver Lp(a) factory; Phase 1 only — not proven to prevent heart attacks yet. CTA: ask for Lp(a) once.

Music: short epic hybrid orchestral sting with progression (not a loop). End with stay vital ONCE.

High energy cuts, scientifically correct animations, cinematic grade color and depth.
LinkedIn
Write a ready-to-paste LinkedIn post as Andres Zuleta MD MMM (Doctor Zuleta / ThriveMed) on Kylo-11, matching his liquid-biopsy LinkedIn style.

STYLE
- Short punchy paragraphs (1 to 3 sentences), mobile white space
- Order: hook → problem → The Lancet 2026 finding → GROUNDBREAKING “For the first time…” beat (specific) → mechanism → FUTURE STAKES “This matters for the future because it could mean…” beat → takeaways → honest Phase 1 caveats → memorable closer → CTA → hashtags
- CTA exactly: “Full study linked in the comments.”
- NEVER use the word longevity (or longevity medicine / anti-aging). Closer = proactive healthcare / new way of doing care / genetics-aware prevention.
- Spell Kylo-11 correctly (never KYLLO)
- No em dashes or en dashes. Prefer commas, periods, colons, or “to” for ranges.
- Attach note: ONE real study figure only (study-fig1-lpa-over-time.png)
- Groundbreaking beat must be concrete (e.g. first-in-human; first time a single gene-silencing dose held ~95 to 97% Lp(a) drop for nearly a year). Do not invent firsts the paper does not support.
- Future-stakes beat must stay conditional (could mean / if later outcome trials confirm). Never claim heart-attack prevention from Phase 1 alone.

FACTS
- Lancet Phase 1 Kylo-11 long-duration siRNA for Lp(a); Sarraju / Cleveland Clinic
- One SC injection; about 53 to 97% Lp(a) drop at 48 weeks; high doses about 95 to 97% nearly a year
- Lp(a) about 80 to 90% genetic; under-tested; no approved Lp(a)-specific drug yet
- Phase 1 = safety + biomarker only, NOT CV outcome proof; Phase 2 underway
- DOI https://doi.org/10.1016/S0140-6736(26)01484-4

Also output a pin-comment with the DOI and Cleveland Clinic release link.
X
Write an X/Twitter post as Doctor Zuleta / ThriveMed on Kylo-11 in Andres’s LinkedIn-derived social style, compressed for X.

DELIVER
A) Preferred: 3–5 tweet thread (hook → journal/result → mechanism → caveats → closer + CTA)
B) Alternate: one post under ~280 characters (link/DOI can sit in reply)

RULES
- Short punchy lines; no longevity wording; spell Kylo-11 never KYLLO
- Phase 1 honesty: biomarker/safety only — no heart-attack prevention claims
- CTA: Full study linked in the comments
- Hashtags on final tweet
- Image note: attach ONE real study figure (study-fig1.png) on tweet 1

FACTS
Lancet 2026 Phase 1 Kylo-11 siRNA Lp(a); Sarraju/Cleveland Clinic; one injection; ~53–97% at 48 weeks; high doses ~95–97% ~1 year; Lp(a) 80–90% genetic; under-tested; Phase 2 underway; DOI https://doi.org/10.1016/S0140-6736(26)01484-4
Reusable social template
# Reusable social prompt — Doctor Zuleta LinkedIn / X

Distilled from Andres’s liquid-biopsy LinkedIn example (Sep 2026) and applied to Kylo-11. Paste this into Cursor / ChatGPT with a new paper’s PDF, DOI, or notes.

---

## PROMPT (copy everything below)

```
You are writing as Andres Zuleta MD MMM (Doctor Zuleta / ThriveMed) for LinkedIn and X.

VOICE & RULES
- Short punchy paragraphs (1–3 sentences). Lots of white space for mobile.
- Professional, clear, human — not hype, not academic fog.
- NEVER use the word “longevity” (or longevity medicine / anti-aging). Frame as: proactive healthcare, genetics-aware risk detection, a new way of doing care / new standard of care, expanding human vitality through better clinical practice.
- Spell drug/device names exactly as in the paper. Never invent spellings.
- No invented clinical claims. Separate “what the study measured” from “what it proves.”
- CTA line exactly: “Full study linked in the comments.”
- End with 4–6 relevant hashtags.
- Instruct to attach ONE real study figure (not stock art) as the visual.
- No em dashes or en dashes in LinkedIn post body. Prefer commas, periods, colons, or “to” for ranges.
- Must include a specific “For the first time…” groundbreaking beat and a “This matters for the future because it could mean…” beat. Keep outcome hopes conditional. Never claim heart-attack prevention from Phase 1 alone.

STRUCTURE (follow this order)
STRUCTURE (follow this order)
1) HOOK: startling stat or systemic problem (what’s broken / ignored).
2) PROBLEM: why it matters in plain language (who doesn’t know, what’s missing from usual care).
3) JOURNAL FINDING: name the high-authority journal + year + one crisp what-happened sentence (who / what intervention / key number).
4) GROUNDBREAKING (“first time…”): be specific about what is first or newly possible in humans. Name the concrete first (e.g. first-in-human, first time a single dose held X% for nearly a year). Do not invent “firsts” the paper does not support.
5) MECHANISM: plain-language how it works (one strong analogy max).
6) FUTURE STAKES (“this matters for the future because it could mean…”): one clear paragraph on why the finding matters if later evidence holds, while staying honest that outcomes are not proven yet.
7) BENEFITS / TAKEAWAYS: specific numbers and practical meaning; short fragment sentences OK for rhythm.
8) CAVEATS: honest limits (phase, sample, what is NOT proven). “Is it perfect? No…” energy is good.
9) CLOSER: memorable paradigm line (reactive to proactive; listening to biology; new way of doing care). NOT longevity.
10) CTA: “Full study linked in the comments.”
11) HASHTAGS
12) IMAGE NOTE: attach one actual figure from the study.

ALSO PRODUCE
A) LinkedIn post (full length, ready to paste)
B) X version: either a 3–5 tweet thread OR one tight post under the character limit
C) Pin-comment text with DOI / open-access link

INPUT PAPER
Title:
Journal / date:
Authors / institution:
DOI:
Key numbers (dose, %, duration, N):
Mechanism (1 sentence):
What we CAN claim:
What we MUST NOT claim:
Audience CTA (lab / behavior / follow science):
Preferred hashtags (optional):
```

---

## Structure cheat-sheet (from liquid-biopsy example)

| Beat | Liquid-biopsy example | Kylo-11 application |
|---|---|---|
| Hook | “60% of cancers diagnosed stage 3–4…” | Most people with high Lp(a) never tested |
| Journal | Nature Medicine landmark review | The Lancet Phase 1 2026 |
| Mechanism | ctDNA fragments in blood | siRNA mute button on liver Lp(a) factory |
| Caveats | False positives; pathways undefined | Phase 1; not outcome data; not approved |
| Closer | “The blood already knows…” | Proactive / genetics-aware care — new way of doing healthcare |
| CTA | Full study linked in the comments | Same |
| Visual | One real study figure | One real study figure |

---

## Hard bans
- Word: longevity (any form)
- Outcome claims without outcome data
- “Approved / available / cures”
- Wrong drug spelling (e.g. KYLLO instead of Kylo-11)
- Multiple images or stock hero art instead of one study figure

07 Social preview

How each post will look on-platform. Logos mark LinkedIn, X, Instagram, TikTok, and YouTube.

LinkedIn · how it will look
Andres Zuleta
Andres Zuleta, MD · Doctor Zuleta
Founder, ThriveMed · Proactive clinical care
Just now · 🌐
Most people with a high heart-disease risk marker have never been tested for it. Not because the lab doesn’t exist, but because lipoprotein(a), or Lp(a), sits outside the usual cholesterol panel. It’s about 80 to 90% genetic. Diet and exercise barely move it. And there is still no approved drug built specifically to lower it. The Lancet just published a first-in-human Phase 1 trial of Kylo-11, a long-duration small interfering RNA (siRNA). Lead work from Ashish Sarraju, M.D., and colleagues at Cleveland Clinic. Here is why this is groundbreaking. For the first time in humans, a single subcutaneous gene-silencing injection drove Lp(a) down by about 53 to 97% at 48 weeks, and at the highest doses about 95 to 97%, with that drop lasting nearly a year. Not a daily pill. Not a weekly shot. One dose, then a year-scale mute on a risk factor we have long treated as basically untreatable. How? Think of a mute button for the liver’s Lp(a) factory. Kylo-11’s siRNA turns down production of apo(a), the building block of Lp(a). Less apo(a) made means far fewer Lp(a) particles assembled. This matters for the future because it could mean we finally get a real path to modify inherited Lp(a) risk that lifestyle cannot fix. If later outcome trials confirm clinical benefit, it could change how we think about lifelong cardiovascular prevention for people born with high Lp(a): test once, know the number, and follow therapies that actually reach the genetic dial. Is it proven to prevent heart attacks today? No. This is Phase 1: safety and biomarker lowering, not cardiovascular outcomes. Not approved. Not in clinic yet. Phase 2 is already underway. But the trajectory matters. A risk factor we used to shrug at as “untreatable” just got a year-long mute in humans. That is a signal that proactive, genetics-aware care is rewriting what we can measure and, eventually, what we may be able to modify. You can’t feel high Lp(a). You can’t diet it away. One blood test, often once in a lifetime, tells you where you stand. This is a new way of doing healthcare: know the inherited risk early, then follow the science with clear eyes. Full study linked in the comments. #Lp(a) #LipoproteinA #Cardiology #PreventiveCare #siRNA #Kylo11 #TheLancet #ThriveMed
Study figure: median percent change in Lp(a) over time
👍💡 12824 comments · 11 reposts
LikeCommentRepostSend
X / Twitter — thread preview
Doctor Zuleta @DoctorZuleta · 1/5
Most people with high Lp(a) don’t know it. It’s ~80–90% genetic. Diet barely moves it. Still no approved Lp(a)-specific drug. And it’s under-tested.
Study figure
Doctor Zuleta @DoctorZuleta · 2/5
The Lancet (2026) Phase 1 Kylo-11 — Sarraju / Cleveland Clinic. One injection. ~48 weeks of follow-up.
Doctor Zuleta @DoctorZuleta · 3/5
Lp(a) dropped ~53–97%. Highest doses ~95–97% for nearly a year. Mute button for the liver’s Lp(a) factory (less apo(a) → less Lp(a)).
YouTube — video cards
5-min YouTube thumbnail 7:07

Kylo-11 & Lp(a): The Lab Most People Never Get

Doctor Zuleta · ThriveMed · 5-min
3-min YouTube thumbnail 3:27

Ask Once for an Lp(a) Lab — Kylo-11 Phase 1

Doctor Zuleta · ThriveMed · 3-min
Instagram — Reel / post frame
doctorzuleta · Follow
Instagram Reel cover
doctorzuleta Most people never get an Lp(a) test. Lancet Phase 1: one Kylo-11 shot. Be proactive. #Lpa #Kylo11
TikTok — vertical frame
TikTok cover
@doctorzuleta
Lp(a) is genetic. One lab. Be proactive. #Lpa #Kylo11 #fyp

08 Locked thumbnails

Assigned posters for the three HeyGen videos (ChatGPT directions locked).

5-min locked thumbnail
5-minthumb-5min.png · ChatGPT B 97% DROP
3-min locked thumbnail
3-minthumb-3min.png · ChatGPT C ASK FOR THIS LAB
Reels locked thumbnail
Reelsthumb-reels.png · ChatGPT E TEST Lp(a)

09 Sources

  1. Sarraju A, Du X, Zhou L, et al. Safety and lipoprotein(a)-lowering effects of Kylo-11… phase 1 trial. The Lancet. Online Aug 28, 2026. DOI: https://doi.org/10.1016/S0140-6736(26)01484-4
  2. Cleveland Clinic Newsroom. First in Human Long-Acting Gene Silencing Therapy Significantly Lowers Heart Disease Risk Marker with One Injection. Aug 28, 2026. newsroom.clevelandclinic.org/…

Educational content for ThriveMed / Doctor Zuleta. Not medical advice. Discuss testing and treatment decisions with your own clinician.

Videos Social Top